Regeneron's bid to acquire the bankrupt genetic testing firm 23andMe for $256 million has likely come to an end.

CT is your last chance to file a claim with 23andMe for a 2023 data breach that may have compromised your genetic data.

A bankruptcy court approved the $305M sale of 23andMe to a nonprofit led by Anne Wojcicki, raising questions about data ...

A bankruptcy court gave the green light for TTAM Research Institute - a firm launched by 23andMe's co-founder and former CEO ...

Former 23andMe CEO Anne Wojcicki now runs TTAM Research Institute, which outbid Regeneron in an auction for the bankrupt company’s assets.

The DNA data of millions of people who used 23andMe's services won't be sold to a pharmaceutical company. A bankruptcy judge greenlighted the sale of the remnants of the firm, including its wealth of ...

Walsh on Friday, marks the end of a monthslong bidding war between TTAM and Regeneron Pharmaceuticals — a biotech ... Under the deal, TTAM will acquire 23andMe’s signature “Personal Genome Service” ...

Regeneron Pharmaceuticals (REGN) exits buyout race for 23andMe as Anne Wojcicki's TTAM Research offers a superior $305M bid. Read more here.

Genetic testing company 23andMe can proceed with a $305 million sale to the company’s co-founder Anne Wojcicki after a U.S.

23andMe Holding Co. will be sold to TTAM Research Institute, a genetics-led healthcare company based in California and led by 23andMe co-founder and former CEO Anne Wojcicki.

Earlier, drugmaker Regeneron Pharmaceuticals was set to buy 23andMe. Then a bankruptcy judge reopened the ... its users' personal information could be sold as part of a merger, acquisition or sale of ...

States with privacy objections to the sale have until July 7 to reach a stay to appeal the case. TTAM, a nonprofit started by ...